Silymarin (Silybum marianum [L.] Gaertn. [Asteraceae]) is a promising agent for cancer prevention, adjuvant cancer treatment, and reduction of iatrogenic toxicity. Although it is safe and free of serious adverse side effects, few studies have evaluated its use alongside conventional cytotoxic therapies, and adverse events associated with long-term administration are uncertain. Although it may prevent some types of cancer, its promotion of tissue regeneration and its potential estrogen activity could promote the growth of some tumors. Further clinical trials using authenticated fractions of silymarin as simple and complex derivatives are required prior to any general recommendations. Future research should focus on authentication of active chemicals, pharmacokinetics, adverse interactions and quality control, prevention of cancer initiation and progression, adjuvant therapy for specific cancers, and prevention of toxicity from anticancer therapies.
Silymarin is a mixture of flavonolignans isolated mainly from the fruits and seeds of milk thistle, Silybum marianum (L.) Gaertn. (Asteraceae). Silymarin is the main active constituent and is the collective name for the flavonolignans silybin, silydianin, and silychristin. Lignans are a broad category of chemical compounds that are widely distributed in nature and display a range of biological activities. The extensive pharmaceutical use of lignans is linked to their antitumor, antiviral, hepatoprotective, and tissue-regenerative properties. As is common for many botanicals that contain complex mixtures, milk thistle manifests a range of possible clinical benefits. The clinical importance of these potential benefits remains to be proven.
As with most phytoceutical research, there are considerable challenges for the further development of Silybum marianum as a therapeutic agent for cancer patients. Standardization of herbal extracts, especially complex mixtures, is mandatory. However, the tools to enable this to be carried out are only now being developed. Therefore, the hurdles are much higher than for the evaluation of conventional pharmaceuticals, and resources have been limited.
Future research should focus on the following categories:
We require more patient-based studies to examine the uptake, bioavailability, pharmacodynamics, pharmacokinetics, and efficacy of the complex botanicals, compared with simple extracts. Four areas of authenticity research should be emphasized: (a) identification and characterization of botanical ingredients, (b) assessment of the bioavailability and bioactivity of botanical ingredients, (c) identification of active constituents and elucidation of their mechanisms of action, and (d) investigation of potential health effects of botanicals. Adverse effects, such as interaction with radiotherapy, need to be evaluated. The formation of multidisciplinary teams to perform the research of this initiative is essential. For example, collaborations among botanists, natural products chemists, pharmacologists, pharmacognosists, and clinical investigators would be appropriate.
In the realm of cancer treatment, the same rules that apply to pharmaceuticals should apply to the regulation of natural health products (NHP). Guidelines and large resources are necessary to take any NHP from quality assurance through studies of efficacy and compliance with the stringent government regulations that apply to drugs. Quality assurance requires efficient and practical measures of batch-to-batch consistency. The laboratory processes for evaluation of NHPs are often scattered between various institutions, and there is no formal agency for registering their chemical and biological profiles or fingerprints. Many of the hurdles in developing and validating analytical methods for NHPs are not encountered when evaluating other types of products. For example, in many cases, the active constituents of NHPs are not known, and appropriate marker substances must be selected. The natural variability of many of these products also complicates method development and validation. When instability of many of the active components and marker compounds after removal from the plant matrix is factored in, the need for agreement on a single, rugged, thoroughly validated analytical method becomes clear.
The lack of regulation of NHPs, compared with pharmaceutical products, raises issues with each product. There is wide variation in the composition of similar botanical agents. Even within the same species, biological variation attributable to differences in soil conditions, moisture, temperature, and harvesting conditions may lead to considerable variability in the concentrations of the bioactive constituents. Activity of the NHP may vary among the capsule, powder, and suspension forms. Given the concerns about standardization, the formulation used in the clinical trial needs to be precisely stated. When possible, a single lot should be used throughout the trial. In addition, if the study design includes the use of a placebo, there is a requirement to ensure that the placebo is identical in appearance, taste, and odor with the NHP being studied, and it should not be associated with biological activity of its own. Stability testing at regular intervals throughout the conduct of the trial is recommended to ensure that the product remains stable over the course of study. Quality testing to ensure minimally acceptable tolerances with regard to heavy metal content, bacterial and fungal counts (especially in the immunocompromised patient with cancer), pesticide residues, and potential contamination with prescription pharmaceuticals is highly recommended. Independent confirmation is preferred.
Other issues to consider are the appropriateness of the marker compounds selected for the botanical and whether the method can be used for both raw materials and finished products. In many cases, matrix interferences result in the methods used for raw materials not being applicable for finished products. In addition, analytical standards are either extremely expensive to develop or nonexistent. Benchmarks for the validity of analytical methods are required. Effectively addressing all of these challenges requires adherence to a comprehensive and strictly defined method development process. 2 An example of a network of collaboration is AOAC International, 3 a 120-year-old not-for-profit scientific association committed to worldwide confidence in analytical results. The National Institute of Standards and Technology is developing standard reference materials (SRMs) based on dietary supplements, with certified values for organic constituents and selected trace elements. These materials are provided primarily for use in method development and as control materials. The SRMs will assist manufacturers of dietary supplements in characterizing raw materials for potency, authenticity, and contamination or adulteration. In addition, the SRMs will assist in assessment of consistency and quality in finished products. 4 Analytical techniques that look at a suite of compounds, including their respective ratios, provide a more rational approach to the authentication and quality assessment of NHPs. Chromatographic fingerprint analysis may be used for determining the identity, stability, and consistency of NHPs as well as the identification of adulterants. 5 Silybum marianum mainly contains flavonolignans. Some antitumor and antiviral lignans have been discovered and developed using both chemical and bioactivity-directed fractionation and isolation along with rational drug design-based structural modification and analog synthesis approaches. A single chemical extract becomes a pharmaceutical agent in contrast to the combination that may have either synergistic or redundant activity. The issue becomes even more complex when isomers are also considered. Controversy exists regarding whether chemically modified plant extracts are still natural therapies. Pragmatically, this should not be an issue because both virgin extracts and modified extracts require equivalent safety and efficacy evaluation when used for the treatment of cancer patients. Currently, there is no standard for determining consistency of content between different preparations. Standardization may be relatively nonspecific, such as agricultural growth conditions or measuring the total percentage of lipid-soluble extracts; more specific, such as standardization to a single chemical component; or very specific by using a combination of techniques that analyze the levels of all chemical constituents by spectography and evaluation of biological activities.
Only more recently has the technology become available to measure both chemical content and biological activities, including some innovative genomic techniques. However, until we can accurately reproduce identical complex mixtures with consistent biological activity, the results of clinical trials cannot be generalized. This is well illustrated by the recent negative clinical trial of a saw palmetto extract for prostatic hypertrophy. 6 There must be assurance that the dose administered gives rise to plasma and/or target tissue concentrations consistent with those required to produce effects in vitro. One primary fault of many clinical studies of botanicals is that adequate pharmacokinetic analyses are not completed before initiating efficacy trials. Some botanicals may fail in efficacy trials, not because the botanical is itself without activity but because the dosing was not sufficient to achieve pharmacologically meaningful concentrations. 7 Bioavailability needs to be optimized before clinical trials. Milk thistle flavonolignans are lipophilic, and delivery systems should take this into account. Equivalent levels used in preclinical studies must be reproduced in human tissues. An example of an applied translational analysis of pharmacokinetics is in the study by Flaig et al. 8 They provide the best evidence that silibinin can be administered to humans at doses producing anticancer-relevant concentrations with minimal or no side effects. This study used the largest doses to date, ranging from 2.5 to 20 g of silibinin-phosphatidylcholine (Indena's Siliphos brand "silybin-phytosome") daily, administered in 3 divided doses for 4 weeks to 13 men with a history of prostate carcinoma. A dose of 5 to 10 g/d was required to achieve mean peak plasma concentrations above 25 µM silibinin equivalents. However, escalation to 15 to 20 g/d did not increase concentrations above 50 µM silibinin equivalents and was discontinued because of asymptomatic hyperbilirubinemia. The halflife of plasma silibinin ranged from 1.8 to 5 hours, consistent with previous studies, and there was extensive glucuronidation. The data suggest that a milk thistle extract administered to human volunteers can be achieved in plasma at concentrations of silibinin equivalents consistent with inhibition of prostate carcinoma cell growth in culture. However, it may interfere with the glucuronidation of some drugs, such as irinotecan. Several reports have also appeared suggesting that silibinin or silymarin can inhibit some isoforms of the cytochrome P450 family, 9 resulting in potential interactions with chemotherapy drugs. Kroll et al (in this issue) advise, "Clinicians should be aware that high doses of milk thistle extracts, perhaps greater than 5 g/d, may have the potential to inhibit the metabolism of other drugs that are substrates for CYP3A4 or CYP2C9. Investigators conducting future high-dose studies may also wish to consider investigating the disposition of CYP model substrates to address this important question." Current research in drug discovery from medicinal plants involves a multifaceted approach combining botanical, phytochemical, biological, and molecular techniques. Medicinal plant drug discovery continues to provide new and important leads against various pharmacological targets. Preclinical studies are necessary to test efficacy in animal models. In addition, pharmacokinetic data are necessary from both direct measurements and modeling. 10 Metabolic effects and interactions require evaluation, and safety remains paramount. 11, 12 Appropriate standardization of phytochemicals is required, and this will be enabled by networking and comparison of techniques and results. 13, 14 The challenges of authenticating the content of a complex mixture of chemicals, maintaining batch-to-batch consistency, and evaluating efficacy through preclinical and clinical studies are exemplified by the design and development of a red clover standardized extract for evaluation in phase I and phase II clinical trials. 15 Each fraction from milk thistle may have biologically distinct activity. The relative importance of each compound is gradually being demonstrated, as distinct fractions are isolated from silymarin or silibinin. The importance of mixtures or pure compounds will depend on the clinical endpoint that is being studied. For example, as discussed elsewhere in this issue by Kroll et al, the silymarin mixture has been shown to contain a modest ligand for the β form estrogen receptor (ERβ). ERβ expression may prevent breast cancer growth and serve as an antagonist to the mitogenic effects of ERβ. Transcriptional activation studies have revealed that silybin B and taxifolin are the only compounds in silymarin capable of stimulating an estrogenresponsive reporter plasmid construct in breast cancer cells in culture. Working with prostate carcinoma cells in culture, 4 compounds had the most consistent antiproliferative effects: silybin A, silybin B, isosilybin A, and isosilybin B. 16 In the androgen-dependent LNCaP prostate carcinoma cell line, prostate-specific antigen (PSA) secretion was most effectively suppressed by isosilybin A and isosilybin B. Therefore, a combination of these 2 compounds, which Kroll et al term "isosilibinin," may be preferable for future studies in prostate carcinoma. On the other hand, the free radical scavenging activity of pure compounds is reported to vary considerably, with silydianin and silychristin exhibiting 2-to 10-fold greater potency than the silibinin mixture. Silydianin and silychristin are present exclusively in silymarin; they are absent from silibinin. This factor accounts for the observation that silymarin is 8-fold more potent than silibinin as a free radical scavenger. To reiterate Kroll et al, "As biological studies progress, it remains important to make the distinction between silymarin and silibinin and their respective and distinct compositions." They also recommend that future pharmacokinetic studies use the molarity term only for pure compounds but continue to use the term "µM silibinin equivalents" to refer to studies that treat silibinin as a single compound.
Prevention of Cancer Initiation and Progression
Silibinin constitutes approximately 40% (w/w) of silymarin and has shown comparable biological effects to silymarin against cancer. Silymarin and silibinin possess most of the desirable characteristics of an ideal cancer chemopreventive agent. They are nontoxic to normal cells, selectively inhibit the growth of cancer cells, and are biologically available following its oral administration. They demonstrate antioxidant and anti-inflammatory properties, an inhibitory effect on epidermal growth factor receptor (EGFR) signaling, alteration in cell cycle progression, and apoptotic effect on cancer cells. The oxidative stress condition, if not eliminated, leads to generation of free radicals and reactive oxygen species, such as the superoxide anion, hydroxyl radical, peroxyl radical, alkoxyl radical, hydroperoxyl radical, and hydrogen peroxide, which can either directly or indirectly modify a number of biologically important molecules including DNA, protein, and lipid-rich membranes. Silymarin displays multiple activities that suppress inflammation and cell proliferation. [16] [17] [18] It inhibits both ligand-caused activation of receptor tyrosine kinase EGFR and its intrinsic kinase activity. Apoptosis is a major contributor in cell death caused by silymarin at higher doses. Silymarin possesses strong anti-inflammatory potential. The up-regulation of tumor necrosis factor (TNF)-α is 1 of the common mechanisms of tumor promotion. Inhibition of TNF-α mRNA expression by silymarin could be an important strategy in cancer chemoprevention. Inflammation is also mediated by lipoxygenase and cyclooxygenase (COX) enzymes. Silymarin inhibits COX-2 expression and COX-2 enzyme activity in terms of prostaglandin E 2 , prostaglandin F 2α and prostaglandin D 2 formation in mouse skin epidermis. 19 Further work is in progress to evaluate the effect of silibinin on various DNA repair pathways following ultraviolet (UV) B exposure. The available experimental information suggests that silymarin is a promising chemopreventive and pharmacologically safe agent that can be tested against skin cancer in human beings. Moreover, silymarin may favorably supplement sunscreen protection and provide additional antiphotocarcinogenic protection. 20 More definitive information is needed on active constituents, synergistic mixtures, dose requirements, and adverse activities in human subjects.
Derivatives from milk thistle may be a good preventive and therapeutic intervention for viral hepatitis. Infection with hepatitis B and C is a major problem in Asia and results in a very high incidence of hepatocellular carcinoma. 21 Therapies that could reduce hepatic inflammation may reduce the progression rate to hepatocellular carcinoma. Clinical trials are required to evaluate the effect of various forms of silymarin on tumor initiation and promotion. Silymarin treatment in type II diabetic patients for 4 months improved the glycemic profile. 22 Because recent evidence suggests that the high insulin levels of type II diabetes may be associated with an increase in breast and colorectal cancer, it is intriguing to speculate that silymarin could reduce cancer risk through improved diabetic control. 23 Silibinin has intestinal cancer chemopreventive efficacy in rodents. It is a strong antioxidant and modulates the insulin-like growth factor (IGF) system by increasing circulating levels of IGF-binding protein 3 and decreasing levels of IGF-I. High silibinin levels are achieved in human colorectal mucosa after consumption of safe silibinin doses. 24 This supports its further exploration as a potential human colorectal cancer chemopreventive agent.
Further investigation in clinical trials will focus on the following: anticancer activities, antidiabetic activity, anti-inflammatory effects, and the influence of silymarin compounds on the formation of catecholestrogen-quinones that are known to produce carcinogenic depurinating DNA adducts within cells. 25 These studies will require long-term follow-up and are probably best implemented in patients at high risk for cancer development, such as those with solar skin damage, personal history or family history of colon cancer, hepatitis, and diabetes. INTEGRATIVE CANCER THERAPIES 6(2); 2007
Adjuvant Therapy for Specific Cancers
Both flavonoids and lignans are often loosely grouped together with isoflavonoids, phytosterols, and coumestans into a category of compounds known as phytoestrogens. There are structural and chemical similarities between flavonoids and human steroid and thyroid hormones. Molecular biologists have begun studying the complex hormone-like actions of flavonoids, including the modulation of various enzyme activities and signaling pathways. Eventually this may lead to a better understanding of how diets rich in phytoestrogens help protect against a variety of cancers, including breast cancer, prostate cancer, and colon cancer. Preclinical evidence suggests that milk thistle enhances new cell growth when needed for repair but often arrests cell division in tumors. The flavonoids in milk thistle seem to have a special affinity for type II estrogen receptors, where they act as a partial agonist, thereby inhibiting the effects of endogenous estrogen. There is also emerging evidence that milk thistle is a COX-2 inhibitor. In other words, it can inhibit an inflammatory prostaglandin pathway that enhances cancer promotion. Among the lignans, only podophyllotoxin and some of its analogs (eg, etoposide and teniposide) have shown clear efficacy and appropriate safety to be used in the clinic as antiviral and anticancer drugs, respectively. 26 These analogs are quite toxic if not used with appropriate caution. The unmodified constituents in milk thistle are relatively safe.
Prostate cancer cells manifest genetic modifications that result in uncontrolled growth, loss of the apoptotic response, and secretion of proangiogenic factors. In the laboratory, silibinin appears to reverse these events in PCA cells. 27 Silibinin inhibits lung tumor angiogenesis in an animal model and merits investigation as a chemopreventive agent for suppressing lung cancer progression. Silibinin, the major active component of silymarin, has shown promising efficacy. Silibinin manifests pleiotropic anticancer effects leading to cell growth inhibition in culture and nude mice. 28 Silibinin also synergizes the therapeutic effects of doxorubicin in PCA cells, making it a strong candidate for combination chemotherapy. It also inhibits the secretion of proangiogenic factors from tumor cells and causes growth inhibition and apoptotic death of endothelial cells. 16, 29 From this preclinical evidence of efficacy and low toxicity, silibinin is an excellent candidate for phase I clinical trials in prostate cancer. Because prostate cancer often produces a measurable blood marker, PSA, biochemical evaluation of response is quite sensitive. Silymarin demonstrates synergistic activity with cisplatin and doxorubicin in vitro. 30, 31 In animal experiments, silymarin offsets the kidney toxicity of cisplatin, a good example of the mixed clinical benefits that can be derived from a complex mixture. 32 Well-designed clinical trials require resources, and many investigators have been challenged in obtaining sufficient funds, especially for the crucial early stages of investigation, such as dose and schedule determination, and pilot studies to estimate effect sizes. There is a great need to enhance the funding opportunities for such important preliminary studies. Strong research designs are necessary to evaluate NHPs and ultimately influence clinical practice and public awareness. The risk-benefit ratio should be assessed, especially if the agent is administered in conjunction with conventional chemotherapy or radiation. Randomized controlled trials (RCTs) are still the gold standard to evaluate both efficacy and safety of medical interventions. However, in general, RCTs are not designed or powered to pick up adverse events. Nor are they long enough to detect long-term adverse effects. Choice of intervention is based on preclinical and phase I pharmacokinetic data. Silibinin is the most active flavonolignan in silymarin, and most capsules are standardized to this compound, but many variations of complex mixtures and single extracts are available and may critically affect clinical outcome. A full phytochemical and biological profile is preferable before commencing any clinical study.
Clinical studies of milk thistle extracts generally have suffered from the same shortcomings found in many other trials of herbal medicines: small sample size, lack of appropriate randomization, blinding, various periods of treatment, lack of information about type and dose of extract and product characterization, ill-defined patient population, and a lack of etiology, severity of disease, and discussion of potential confounders. Both methodological quality and reporting of milk thistle are improving and will continue to improve if researchers in academia and industry follow available guidelines and regulatory requirements for the conduct and reporting of clinical trials. Guidelines for reporting RCTs of herbal medicines have recently been published by the Consolidated Standards of Reporting Trials group. 33 There are also a number of regulatory guidelines available from different countries that will aid in the development of high-quality clinical trials using both a well-characterized, well-defined product and good clinical practices.
Several factors need to be considered in the development of sound study designs. Because data on the dose and schedule of administration may be limited for many NHPs, consideration should be given to designing the study according to the phase I model, which is most often used for conventional drug evaluation. However, this model may be limited in that a maximum tolerated dose may not be achieved for many NHPs. This model also may not ascertain the effects of chronic administration, more typical of NHPs. The starting dose may be based more on traditional practice rather than experimental data. Effects may be measured using a surrogate marker, but if the biological mechanism of the NHP is not known, a surrogate marker may not be available.
Efficacy studies as typically defined by the phase III study design may be premature for many NHPs. Factors to be considered in designing an efficacy trial include the identification of an appropriate comparison group and justification for the estimates of effect sizes, with appropriate sample size considerations. These factors underscore the need for pilot data that will also allow identification of appropriate outcomes and time points for assessment. The study design needs to also account for the risk of interactions with conventional therapies because patients are more likely to use the therapies concomitantly. Patients may also be using other self-prescribed NHPs during the trial period. Compliance in taking the NHP during the study should be checked.
Attention to a number of regulatory issues will also improve the conduct of the trial. Researchers are highly advised to conduct studies of NHPs under an investigatorinitiated investigational new drug application with the US Food and Drug Administration, Natural Health Products Directorate of Health Canada, or an equivalent agency. Collaboration with a research pharmacy to ensure appropriate NHP distribution and blinding, if appropriate, is crucial. Clinical trials must be reviewed and monitored by institutional review boards. Unfortunately, the lack of expertise with NHPs at many institutions often hampers reviews and delays the activation of clinical trials. Data safety monitoring should be performed throughout the study, but institutional monitoring boards may not have members with particular expertise in NHPs. All randomized clinical trials of NHPs should be registered on a clinical trials registry through the National Institutes of Health or a similar agency.
Clinical trials of silymarin in cancer patients are limited and reviewed elsewhere in this issue. Hoh et al 24 reported a trial that translated animal laboratory data into meaningful clinical data to enable the initiation of clinical trials. Here, the hypothesis was tested that administration of oral silibinin generates levels in human blood and colorectal and hepatic tissues consistent with pharmacologic activity. Patients with confirmed colorectal adenocarcinoma received silibinin formulated with phosphatidylcholine (silipide) at dosages of 360, 720, or 1440 mg of silibinin daily for 7 days. Blood and biopsy samples of normal and malignant colorectum or liver were obtained before dosing, and blood and colorectal or hepatic tissues were collected at resection surgery after the final silipide dose. Levels of silibinin were quantified by high-pressure liquid chromatography-UV, and plasma metabolites were identified by liquid chromatographymass spectrometry. Repeated administration of silipide was safe and achieved levels of silibinin of 0.3 to 4 µmol/L in the plasma, 0.3 to 2.5 nmol/g tissue in the liver, and 20 to 141 nmol/g tissue in colorectal tissue. Silibinin monoglucuronide, silibinin diglucuronide, silibinin monosulfate, and silibinin glucuronide sulfate were identified in the plasma. Several doses of milk thistle (silymarin) have been tested both alone and in conjunction with other drugs in several populations. Up to 13 g, divided in 3 daily doses of silibinin phytosome (Siliphos), was evaluated in prostate cancer patients and was determined as the recommended dose to further evaluate anticancer effects of silibin. 5 Dosages of 360, 720, or 1440 mg of silibinin daily for 7 days achieved high silibinin levels in the colorectal mucosa of 24 colorectal cancer patients after consumption of phosphatidylcholine (Silipide). These findings encourage further exploration of silymarin and silibinin as potential agents for the treatment or prevention of colorectal cancer.
Despite some promising results regarding silymarin as an anticancer agent, caution should be exercised. A study on mice showed that silymarin could increase the incidence of mammary tumors, possibly related to its partial estrogen activity. 34 Further phase I and II studies are required in human subjects to determine the optimum preparation of milk thistle, the optimal dosing, efficacy, and potential adverse events. Although there is no clear evidence that silymarin inhibits the activity of radiation on tumor cells, more information is needed in view of its known protective effect against radiation on liver cells. Silymarin has not yet reached prime time for the treatment of cancer and should not be advocated for routine use at this juncture.
Prevention of Toxicity From Anticancer Therapies
Because the liver is the primary organ that cleanses and detoxifies the blood, many detoxification programs include a component of liver support or what is often called "liver cleansing" in the alternative medicine world. Milk thistle is commonly included in detoxification regimens. Although there is preclinical evidence supporting the fact that milk thistle can protect the liver against damage from toxins and stimulate the transcription and activity of phase II detoxification enzymes, no clinical studies have examined the effects of the use of milk thistle for this general detoxification purpose.
Milk thistle has been studied for its use as a hepatoprotectant and for preventing hepatotoxicity from exogenous exposure to known liver toxins. Most of this research is reviewed elsewhere in this issue. Studies have focused mainly on exposures to alcohol and drugs, occupational exposures such as toluene and xylene, and ingestion of Amanita phalloides mushrooms. The mechanisms of action are still poorly understood. The data indicate that silymarin and silibinin act in 4 different ways: (a) as antioxidants, scavengers, and regulators of the intracellular content of glutathione; (b) as cell membrane stabilizers and permeability regulators that prevent hepatotoxic agents from entering hepatocytes; (c) as promoters of ribosomal RNA synthesis, stimulating liver regeneration; and (d) as inhibitors of the transformation of stellate hepatocytes into myofibroblasts, the process responsible for the deposition of collagen fibers leading to cirrhosis.
The key mechanism that ensures hepatoprotection appears to be free radical scavenging. 35 A recent clinical trial in patients with end-stage diabetic nephropathy showed that treatment with silymarin corrected thiol deficiency, increased T-cell activation, and reduced TNF-α, thus normalizing immunoregulatory defects. 36 Silymarin may protect the kidneys from cisplatin toxicity. 37 Milk thistle may also protect the kidney from radiation damage. Administered orally before exposure to gamma radiation, milk thistle had significant protective effects on urea and creatinine serum levels in an animal model. 38, 39 The investigators studied the radioprotective effect of silymarin against radiationinduced hepatotoxicity at 1, 3, and 7 days after irradiation. Whole-body gamma irradiation caused an increase in serum alkaline phosphatase activity as well as liver glutathione reductase and glutathione peroxidase activities on the first postexposure day. However, 3 days after radiation exposure, these parameters showed a significant decrease below the control level, which persisted until the end of the experimental time. Administration of silymarin as single (70 mg/kg) or fractionated (490 mg/kg) oral doses or as an intravenous injection (50 mg/kg) caused significant protection. Intravenous treatment showed the most pronounced protection. The protective effect of silymarin was attributed to its antioxidant and free radical scavenging properties.
In the NCT00055718 study of patients with acute lymphocytic leukemia (ALL), many of the discussed standards for NHP clinical research were applied. 40 This was a multicenter, randomized, phase II screening trial to justify estimates of effect sizes, with appropriate sample size consideration. The primary objective was to evaluate the effect of 28 days of milk thistle supplementation on liver function tests in children with ALL receiving hepatotoxic chemotherapy. A certificate of analysis was obtained from the manufacturer, contaminants were excluded, and there was independent quantification of content of silibinin isomers, silybin A and silybin B. In the phase I study, the ability of milk thistle to affect bilirubin levels was screened, with criteria to move to a phase II study if milk thistle was associated with at least a 25% reduction in bilirubin levels. No adverse effects were observed. In the phase II study, milk thistle was evaluated for a clinically significant (important) effect, such as an association with a lower incidence of subjects requiring dose reductions in chemotherapy. The design of NCT00055718 was rigorous, but the results will apply to that specific formulation and may not apply to other generic preparations. Future studies need to take a similar approach that is consistent with good clinical trials practice.
Conclusion
The current experimental data suggest that silymarin is a promising agent for cancer prevention, adjuvant cancer treatment, and reduction of iatrogenic toxicity. Pharmacokinetic and toxicity studies have not disclosed any issues that could limit the therapeutic use of silymarin. However, caution should be applied to its use with radiotherapy because it could potentially also protect the tumor and because of pharmacokinetic interactions with specific chemotherapies metabolized by CYP enzymes. In addition, we should be cautious about long-term administration. Theoretically, its antioxidant and anti-COX-2 effects could prevent some types of cancer, but its promotion of tissue regeneration, such as in the liver, and its potential estrogen activity may theoretically promote the growth of some tumors. Further clinical trials using expert authentication of milk thistle derivatives as simple and complex derivatives are required prior to any general recommendations.
